Physician profile
Howard M Busch
NPI 1932262516
$717,070.78
in general payments reported to CMS, 2019-2025
55 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $88K · 2021: $148K · 2022: $125K · 2023: $104K · 2024: $74K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $123K · Honoraria: $60K · Food and Beverage: $18K · Travel and Lodging: $18K · Consulting Fee: $6,320 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $123,162.50 |
| Honoraria | $59,918.75 |
| Food and Beverage | $18,455.61 |
| Travel and Lodging | $18,266.64 |
| Consulting Fee | $6,320.00 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $202,587.33 | 2020-2025 | Acthar |
| Amgen INC. | $109,551.63 | 2019-2025 | Krystexxa, Otezla, Tepezza |
| Horizon Therapeutics Plc | $89,352.75 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $54,822.07 | 2020-2025 | Benlysta, Nucala |
| Ani Pharmaceuticals, INC. | $50,485.71 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Astrazeneca Pharmaceuticals LP | $41,140.53 | 2021-2025 | Saphnelo, Flumist Quadrivalent, Evusheld |
| Ucb, INC. | $40,282.76 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Enterprises LLC | $36,376.57 | 2019 | |
| Celgene Corporation | $23,227.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17,097.86 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $15,454.88 | 2021-2025 | Lupkynis |
| Genzyme Corporation | $11,456.52 | 2019-2025 | |
| Abbvie INC. | $7,864.34 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Genentech USA, INC. | $6,715.80 | 2019-2025 | Actemra |
| Janssen Biotech, INC. | $2,065.32 | 2019-2025 | Tremfya |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Busch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.